Vyjuvek (Beremagene Geperpavec-Svdt) Patent Expiration, LOE Window & CMS Spending

Vyjuvek (Beremagene Geperpavec-Svdt) by Krystal Biotech: Off-Patent Genericized (AB Competition), 0 AB generics, $117.2M 2024 CMS Part D & Medicaid spend, and $24,250 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKrystal Biotech
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$117.2M
2024 Medicare Part D Spend$22.7M
2024 Medicaid Spend$94.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($24,250 intro WAC)